Cardiff Oncology
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
11055 Flintkote Ave, San Diego, Californ...Phone Number
(858) 952-7570Website
www.cardiffoncology.comRevenue
<$5 MillionStock Symbol
CRDFIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Cardiff Oncology
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Explore more
Cardiff Oncology Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cardiff Oncology your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Cardiff Oncology, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Cardiff Oncology has new funding data
Check out if Cardiff Oncology is spiking on competitors!
Earning: See what the market has to say on Cardiff Oncology recently announced quarterly report
Check if Cardiff Oncology has recently received funding, and reach out quickly before it becomes old news!
Click to see if Cardiff Oncology had a recent Job posting/layoffs
Product Launch: Get notified when Cardiff Oncology launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Cardiff Oncology
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Cardiff Oncology
Compare insights from companies similar to Cardiff Oncology, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cardiff Oncology is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Cardiff Oncology is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Cardiff Oncology.
Cardiff Oncology financials insights
Gather financial insights about Cardiff Oncology, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Other Financing Round
$13.5M
Cardiff Oncology Tech Stack
A closer look at the technologies used by Cardiff Oncology
Most Recent Scoops
Person-Based
Clinical Operations
Person-Based
Pharmaceuticals, Clinical Operations
Person-Based
Stake & Stock Ownership, Finance
Person-Based
Share Placement, Business Finance, Finance
Person-Based
Stake & Stock Ownership, Finance
Cardiff Oncology News & Media
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update
Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated mCRCCardiff Oncology Announces $10 Million Registered Direct Offering to Strengthen Working Capital
Cardiff Oncology has secured a $10 million registered direct offering, providing additional capital for working capital and general corporate purposes as the company continues advancing its lead oncology program. Key Investor TakeawaysCardiff Oncology (NASDAQ:CRDF) expects to raise approximately $10 million in gross proceeds through a registered direct offering.Cardiff Oncology Announces $10 Million Registered Direct Offering
SAN DIEGO, July 15, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF) (the “Company”), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 8,571,429 shares of its common stock and accompanying warrants to purchase up to an aggregate of 8,571,429 shares of its common stock, at a purchase price of $1.05 per shareCardiff Oncology, Inc. (CRDF) Discusses Updated Phase II CRDF-004 Data on Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer Transcript
Cardiff Oncology, Inc. (CRDF) Discusses Updated Phase II CRDF-004 Data on Onvansertib in First-Line RAS-Mutated Metastatic Colorectal Cancer June 3, 2026...
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding Cardiff Oncology
Sign Up For FreeTo access detailed company insights
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as i... Read More
